Notwithstanding encouraging clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial resistance from PBMs. These insurers are typically creating barriers to reimbursement, like significant price requirements and PA that limit consumer opportunity. Market suggest that… Read More